Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio of two proteins, pTau217 and ß-Amyloid 1-42, which are implicated in ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

Stroke kills millions, but Osaka researchers have unveiled GAI-17, a drug that halts toxic GAPDH clumping, slashes brain ...

Nicotine, an addictive stimulant found in the tobacco plant, can increase the release of dopamine and other neurotransmitters ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

A stroke drug called GAI-17 protected mouse brains even six hours after damage began—and may one day help fight Alzheimer’s ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Scientists have used AI to re-analyse a clinical trial for an Alzheimer's medicine, and identified a group of patients who responded to treatment. The ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.